Understanding liver disease in patients with congenital heart disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to investigate Fontan Associated Liver Disease (FALD) in individuals who have undergone the Fontan procedure for congenital heart disease. Researchers will assess the long-term effects of blood congestion in the liver, which can lead to cirrhosis, by screening participants through medical history, physical exams, and various tests including blood work and liver ultrasounds. The study will also explore novel biomarkers that could help in assessing disease severity and improving treatment decisions for affected patients.

Why it matters

Who can join: the full rules

* INCLUSION CRITERIA:

In order to be eligible to participate in this study, an individual must meet all of the following criteria:

1. Male and female subjects \>= 18 years of age.
2. Past surgical history of Fontan procedure.
3. Prior enrollment in the Liver Diseases Branch protocol 91DK0214
4. Underwent cardiac catheterization or transjugular liver biopsy within ten years prior to the date of screening
5. Approved to proceed by the NIH Cardiology Consult
6. Approved to proceed by the NIH Cardiac Pre-anesthesia Consult

EXCLUSION CRITERIA:

An individual who meets any of the following criteria will be excluded from participation in this study:

1. Evidence of other forms of liver disease that typically result in cirrhosis.
2. Evidence of active Chronic Hepatitis B infection as defined by the presence of hepatitis B surface antigen (HBsAg) in serum and elevated HBV DNA (\>10,000 IU/mL).
3. Hepatitis C as defined by the presence of hepatitis C RNA in serum.
4. Evidence of other liver disease such as primary sclerosing cholangitis, primary biliary cirrhosis, Wilson s disease, autoimmune hepatitis as defined by either liver histology or laboratory abnormalities.
5. Hemochromatosis as defined by presence of 3+ or 4+ stainable iron on liver biopsy or homozygosity for C282Y. Patients with iron saturation indices of \>45% and serum ferritin levels of \>300 ng/ml for men and \>250 ng/ml for women will undergo genetic testing for hemochromatosis.
6. Bile duct obstruction as suggested by imaging studies done within the previous six months.
7. Active substance abuse, such as alcohol, inhaled or injection drugs within the previous one year (assessed during patient interviews or by patient self-report).
8. Evidence of hepatocellular carcinoma; either alpha-fetoprotein (AFP) levels greater than 50 ng/ml (normal \<6.6 ng/ml) and/or ultrasound (or other imaging study) demonstrating a mass suggestive of liver cancer.
9. Evidence of Cholangiocarcinoma.
10. A documented or otherwise stated severe allergic reaction to contrast.
11. Any other severe condition, which in the opinion of the investigators would impede the patient s participation or compliance in the study.
12. Radiation exposure exceeds 5 rems during the past year.
13. Inability to comply or give written informed consent as there is no direct benefit from participation in this study.
14. Female subjects who are currently pregnant will be excluded due to radiation exposure necessary for study completion. In addition, altered hemodynamics may confound the study s results. Following pregnancy, patients may be reconsidered for the study.

Where it's running

• National Institutes of Health Clinical Center
  Bethesda, Maryland, United States Recruiting

Study contacts

• Principal investigator: Theo Heller, M.D. — National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
• Study coordinator: Elenita M Rivera, R.N.
• Email: erivera@cc.nih.gov
• Phone: (301) 435-6125

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Adapting and testing PEN-Plus in Zambian primary care

  Aiming to see if the PEN-Plus package can be adapted and used in two Zambian hospitals to better manage chronic diseases like heart disease, diabetes, hypertension, and sickle cell in primary care.

  Recruiting Centre for Infectious Disease Research in Zambia · Lusaka, Lusaka Province · NCT07753681

• Wireless NIRS Sensor Use in the NICU for Monitoring on Neonates

  A wireless NIRS sensor is tested on infants in the NICU to see how well it stays on and how it notes brain signals when used alongside standard wired sensors.

  Recruiting McGill University Health Centre/Research Institute of the McGill University Health Centre · Montreal, Quebec · NCT07732244

• Screening for lipid disorders in children and teens with chronic diseases to flag cardiovascular risk

  This study tests a blood test and a questionnaire to screen children and teens with chronic conditions for lipid metabolism disorders and familial hyperlipidemia.

  Recruiting Jena University Hospital · Jena · NCT07716488

• Prehabilitation before heart surgery for adults with congenital heart disease

  This study is testing whether a tailored, supervised exercise program before heart surgery helps adults with congenital heart disease perform better and improve fitness.

  Recruiting Liverpool Heart and Chest Hospital NHS Foundation Trust · Liverpool · NCT07700459

• Accessible care model comparing nurse-led versus physician-led transition education for teens and young adults with congenital heart disease

  This project will test whether an accessible care model and nurse-led versus physician-led transition education helps teens and young adults (ages 12–26) with congenital heart disease move successfully from pediatric to adult heart care.

  Recruiting University of Wisconsin, Madison · Madison, Wisconsin · NCT07559253

• Surgical techniques and outcomes across the lifespan in congenital heart disease in China

  See which surgical factors and care patterns affect recovery after heart surgery for people with complex congenital heart disease in China.

  Recruiting China National Center for Cardiovascular Diseases · Beijing · NCT07524998

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.